All News
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.
Read Article
Less Mortality with GLP-1 Agonists in Rheumatic Patients
A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.
Read Article
The Burden of Rheumatoid Arthritis (2018–2020)
A recent study that quantified the economic and humanistic burden of rheumatoid arthritis (RA) in the USA showed significantly higher health care expenditures, particularly medication costs, and suboptimal quality of life in RA.
Read Article
Depends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read Article
Prescription Painkiller Misuse in Chronic Pain Patients
A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.
Read Article
Economic, Personal Burden of RA: Maybe Not So Bad?
Data from a major federal survey indicate that people with rheumatoid arthritis (RA) don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found.
Read Article
Barriers to Treat-to-Target in Rheumatoid Arthritis
A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation.
Read Article
Gout Forecast: 70% Increase by 2050
The Global Burden of Diseases, Injuries, and Risk Factors Study of 2021 has forecasted prevalence of gout to increase by 70% by 2050. In the USA, the prevalence of gout is estimated to be 10.3 million. As of 2020, 55.8 million people globally had gout, with a prevalence of 659.3 per 100 000 (this represents a 22.5% increase since 1990).
Read Article
Lead with Lupus (8.2.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com - leading with lupus because everyone wants to know about lupus!
Read Article
Decline in Physician Trust During the COVID-19 Pandemic
JAMA reports that following the COVID-19 pandemic US adults trust in physicians and hospitals decreased, and was associated with lower odds of COVID vaccination.
Read Article
Location, Location, Location (7.26.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Location matters; Geo-rheumatology?
Read Article
Digital Self Screening for Arthritis Diagnosis
There are numerous impediments to diagnosis or referral; and a new study evaluates patient use of a mobile artificial intelligence (AI)–based symptom checker for diagnoses, but demonstrated only modest accuracy when applied to a cohort of patients with joint symptoms.
Read Article
Patients with Financial Limits Struggle with Medication Adherence
Analysis of the National Health Interview Survey shows that nearly 1 in 5 patients with rheumatologic disease in the United States struggled economically, suffering from food insecurity and cost related medication (CRM) nonadherence.
Read Article
Earlier RA Diagnosis Leads to Lower Costs of Care
A study from the Leiden Early Arthritis Clinic shows that is rheumatoid arthritis (RA) is diagnosed within 12 weeks after symptom onset, treatment costs were lower in both autoantibody-negative and autoantibody-positive RA.
Best Rheumatologists (7.19.2024)
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Read Article
Geography of Arthritis-attributable Pain in the USA
The journal Pain has shown geographic differences in arthritis-attributable pain, arthritis-related outcomes mostly clustered in the Deep South and Appalachia, while severe arthritis pain is more prevalent in the Southwest, Pacific Northwest, Georgia, Florida, and Maine.
Read Article
